Halozyme Therapeutics (HALO) Earnings Date, Estimates & Call Transcripts

$56.23

+0.26 (+0.46%)

(As of 07/26/2024 ET)

Upcoming Earnings Date: Aug. 6
After Market Closes
Confirmed
Actual EPS (May. 7): $0.71 Beat By $0.07
Consensus EPS (May. 7): $0.64

HALO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

HALO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ad American Hartford Gold Group

Prepare for a Recession Unlike Any Other

Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.

GET THE FREE GUIDE

Halozyme Therapeutics Analyst EPS Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2024	3	$0.58	$0.77	$0.69
Q2 2024	3	$0.68	$0.92	$0.78
Q3 2024	3	$0.91	$1.07	$0.98
Q4 2024	3	$0.94	$1.25	$1.11
FY 2024	12	$3.11	$4.01	$3.56
Q1 2025	1	$0.89	$0.89	$0.89
Q2 2025	1	$1.06	$1.06	$1.06
Q3 2025	1	$1.09	$1.09	$1.09
Q4 2025	1	$1.22	$1.22	$1.22
FY 2025	4	$4.26	$4.26	$4.26
Q1 2026	1	$1.44	$1.44	$1.44

HALO Earnings Date and Information

Halozyme Therapeutics last announced its earnings results on May 7th, 2024. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.07. The company earned $195.88 million during the quarter, compared to analyst estimates of $201.72 million. Halozyme Therapeutics has generated $2.42 earnings per share over the last year ($2.42 diluted earnings per share) and currently has a price-to-earnings ratio of 23.2. Earnings for Halozyme Therapeutics are expected to grow by 24.32% in the coming year, from $3.66 to $4.55 per share. Halozyme Therapeutics has confirmed that its next quarterly earnings report will be published on Tuesday, August 6th, 2024. Halozyme Therapeutics will be holding an earnings conference call on Tuesday, August 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call..

Halozyme Therapeutics Earnings History by Quarter

Time Frame

Start Date

End Date

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
8/6/2024 (Confirmed)	-	-	-	-	-	-	-
5/7/2024	Q1 2024	$0.64	$0.71	+$0.07	$0.82	$201.72 million	$195.88 million
2/20/2024	Q4 2023	$0.77	$0.75	($0.02)	$0.85	$235.25 million	$230.04 million
11/6/2023	Q3 2023	$0.67	$0.69	+$0.02	$0.77	$219.47 million	$216.03 million
8/8/2023	Q2 2023	$0.59	$0.68	+$0.09	$0.80	$201.91 million	$221.04 million
5/9/2023	Q1 2023	$0.44	$0.43	($0.01)	$0.57	$174.20 million	$162.14 million
2/21/2023	Q4 2022	$0.43	$0.44	+$0.01	$0.46	$186.07 million	$181.50 million
Get the Latest News and Ratings for HALO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
11/8/2022	Q3 2022	$0.49	$0.70	+$0.21	$0.96	$187.87 million	$208.98 million
8/9/2022	Q2 2022	$0.47	$0.50	+$0.03	$0.84	$156.00 million	$152.37 million
5/10/2022	Q1 2022	$0.45	$0.43	($0.02)	$0.43	$128.25 million	$117.30 million
2/22/2022	Q4 2021	$0.35	$0.39	+$0.04	$0.32	$97.10 million	$102.00 million
11/2/2021	Q3 2021	$0.42	$1.48	+$1.06	($0.44)	$101.94 million	$115.83 million
8/9/2021	Q2 2021	$0.43	$0.62	+$0.19	$0.64	$104.08 million	$136.50 million
5/10/2021	Q1 2021	$0.32	$0.37	+$0.05	$0.49	$84.88 million	$89.02 million
2/23/2021	Q4 2020	$0.56	$0.50	($0.06)	$0.50	$120.75 million	$121.70 million
11/2/2020	Q3 2020	$0.20	$0.25	+$0.05	$0.25	$59.35 million	$65.30 million
8/10/2020	Q2 2020	$0.25	$0.19	($0.06)	$0.19	$65.81 million	$55.22 million
5/11/2020	Q1 2020	($0.02)	($0.04)	($0.02)	($0.04)	$42.96 million	$25.30 million
2/24/2020	Q4 2019	($0.18)	($0.24)	($0.06)	($0.24)	$55.69 million	$53.70 million
11/12/2019	Q3 2019	($0.12)	($0.1712)	($0.0512)	($0.17)	$54.96 million	$46.20 million
8/6/2019	Q2 2019	($0.17)	($0.1006)	+$0.0694	($0.10)	$42.94 million	$39.10 million

Halozyme Therapeutics Earnings - Frequently Asked Questions

When is Halozyme Therapeutics's earnings date?: Halozyme Therapeutics has confirmed that its next quarterly earnings data will be published on Tuesday, August 6th, 2024. Learn more on HALO's earnings history.
What guidance has Halozyme Therapeutics issued on next quarter's earnings?: Halozyme Therapeutics issued an update on its FY 2024 earnings guidance on Thursday, June, 27th. The company provided earnings per share guidance of 3.650-4.050 for the period, compared to the consensus earnings per share estimate of 3.730. The company issued revenue guidance of $935.0 million-$1.0 billion, compared to the consensus revenue estimate of $947.3 million.
Did Halozyme Therapeutics beat their earnings estimates last quarter?: In the previous quarter, Halozyme Therapeutics (NASDAQ:HALO) reported $0.71 earnings per share (EPS) to beat the analysts' consensus estimate of $0.64 by $0.07. Learn more on analysts' earnings estimate vs. HALO's actual earnings.
How much revenue does Halozyme Therapeutics generate each year?: Halozyme Therapeutics (NASDAQ:HALO) has a recorded annual revenue of $829.25 million.
How much profit does Halozyme Therapeutics generate each year?: Halozyme Therapeutics (NASDAQ:HALO) has a recorded net income of $281.59 million. HALO has generated $2.42 earnings per share over the last four quarters.
What is Halozyme Therapeutics's price-to-earnings ratio?: Halozyme Therapeutics (NASDAQ:HALO) has a trailing price-to-earnings ratio of 23.24 and a forward price-to-earnings ratio of 15.36. The price/earnings-to-growth ratio is 0.56.
What is Halozyme Therapeutics's EPS forecast for next year?: Halozyme Therapeutics's earnings are expected to grow from $3.66 per share to $4.55 per share in the next year, which is a 24.32% increase.